scholarly journals Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients

Diagnostics ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 883
Author(s):  
Ken Kudura ◽  
Florentia Dimitriou ◽  
Daniela Mihic-Probst ◽  
Urs J. Muehlematter ◽  
Tim Kutzker ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Fdg Pet ◽  
Clinical Management ◽  
Clinical Routine ◽  
Malignancy Rate ◽  
Pet Ct ◽  
Malignant Lesions ◽  
Melanoma Patients ◽  
Fdg Pet Ct ◽  
The Impact

Background: The use of 18F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomography FDG-PET/CT in clinical routine for staging, treatment response monitoring and post treatment surveillance in metastatic melanoma patients has noticeably increased due to significant improvement of the overall survival rate in melanoma patients. However, determining the dignity of the findings with increased metabolic activity on FDG-PET/CT can be sometimes challenging and may need further investigation. Purpose: We aimed to investigate the malignancy rate of indeterminate findings on FDG-PET/CT in metastatic cutaneous melanoma patients. Methods: This single-center retrospective study included cutaneous melanoma patients who underwent FDG-PET/CT in clinical routine between 2015 and 2017 with findings reported as indeterminate and therefore requiring further evaluation. The dignity of the included findings was determined by subsequent imaging and, if required, additional histopathology. The impact of the outcome on the clinical management was also reported. Results: A total of 842 FDG-PET/CT reports of 244 metastatic cutaneous melanoma patients were reviewed. Sixty indeterminate findings were included. Almost half of all indeterminate findings were lymph nodes, lung nodules and cerebral lesions. In total, 43.3% of all included findings proved to be malignant. 81% of all malignant lesions were metastases of cutaneous melanoma, while 19% of all malignant lesions could be attributed to other primary malignancies, such as lung, breast, thyroid and colorectal cancers. Malignant findings influenced clinical management in 60% of the cases. Conclusion: Indeterminate findings on FDG-PET/CT in metastatic cutaneous melanoma patients should be further investigated. Almost one out of every two indeterminate findings on FDG-PET/CT is malignant. The majority of the findings are melanoma manifestations, however, in a significant percentage, other primary tumors are found. Upon verification, patient management is changed in most cases.

scholarly journals Usefulness of 18F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels

2018 ◽  
Vol 27 (2) ◽  
pp. 66-72 ◽  
Author(s):  
Özge Vural Topuz ◽  
Fatma Arzu Görtan ◽  
Zübeyde Rana Kaya Döner ◽  
Çetin Önsel ◽  
Haluk Burçak Sayman
Keyword(s):  
Lymph Nodes ◽  
Cutaneous Melanoma ◽  
Fdg Pet ◽  
Sentinel Lymph Nodes ◽  
Pet Ct ◽  
Melanoma Patients ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Impact of 18F-FDG-PET/CT on Clinical Management in Patients with Cholangiocellular Carcinoma

BJR|Open ◽  
2021 ◽  
pp. 20210008
Author(s):  
Lena Sophie Kiefer ◽  
Julia Sekler ◽  
Brigitte Gückel ◽  
Mareen Sarah Kraus ◽  
Christian la Fougère ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Clinical Management ◽  
Palliative Treatment ◽  
Treatment Strategies ◽  
Cholangiocellular Carcinoma ◽  
Treatment Goal ◽  
Targeted Biopsy ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
The Impact

Objective: To determine the impact of 18F-FDG-PET/CT on clinical management of patients with cholangiocellular carcinoma (CCA). Methods: Patients with CCA undergoing clinically indicated 18F-FDG-PET/CT between 04/2013 and 08/2018 were prospectively included in a local PET/CT registry study. Intended clinical management (“non-treatment” such as watchful-waiting or additional diagnostic tests, and “palliative” or “curative treatment”) was recorded before and after PET/CT. Changes in intended management after PET/CT were analyzed. Results: 27 patients (mean age: 60 years, IQR: 51.5–67.5 years, 56% males) with 43 PET/CT-examinations were included. Intended management changed in 35/43 cases (81.4%) following PET/CT. Major changes (i.e., between “non-treatment” and “treatment” strategies or between a “curative” and “palliative” treatment goal) occurred in 27/43 (62.8%) cases. Before PET/CT, additional imaging and/or biopsy was intended in 21/43 (48.8%) and 9/43 (20.9%) cases, respectively. After PET/CT, further imaging was carried out in one case and imaging-targeted biopsy in eight cases. Although the absolute number of biopsies after PET/CT did not decrease, in only one of these eight cases biopsy had already been planned before PET/CT, whereas in the other eight cases the originally planned biopsies were dispensable after PET/CT. Conclusions: 18F-FDG-PET/CT significantly impacts clinical management of patients with CCA. It guides decisions on treatment strategy (especially curative vs palliative treatment goal) and on additional tests, particularly by helping referring clinicians to avoid unnecessary imaging and by guiding targeted biopsy. Advances in knowledge: Systematic implementation of 18F-FDG-PET/CT may enable a more appropriate and tailored treatment of patients with CCA, especially in cases of suspected recurrence.

scholarly journals Comparison of the Impact of 68 Ga-DOTATATE and 18 F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors

2016 ◽  
Vol 58 (1) ◽  
pp. 91-96 ◽  
Author(s):  
Emmanouil Panagiotidis ◽  
Alshaima Alshammari ◽  
Sofia Michopoulou ◽  
Evangelia Skoura ◽  
Keval Naik ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Fdg Pet ◽  
Clinical Management ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
The Impact

scholarly journals Malignancy rate of focal thyroid incidentaloma detected by FDG PET–CT: results of a prospective cohort study

2017 ◽  
Vol 6 (6) ◽  
pp. 413-421 ◽  
Author(s):  
Philippe Thuillier ◽  
Nathalie Roudaut ◽  
Geneviève Crouzeix ◽  
Marie Cavarec ◽  
Philippe Robin ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Thyroid Disease ◽  
Fdg Pet ◽  
Prospective Cohort ◽  
Malignancy Rate ◽  
Thyroid Incidentaloma ◽  
Pet Ct ◽  
Malignant Lesions ◽  
Fdg Pet Ct

Objective To evaluate the malignancy rate of focal thyroid incidentaloma (fTI) in a population of patients undergoing a 18F-fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET–CT) for a non-thyroid purpose. Design We conducted a prospective cohort study from January 2013 to November 2014. All consecutive patients referred for a FDG PET–CT were prospectively screened. Patients with known neoplastic thyroid disease were excluded from the analysis. All patients presenting one or more fTI and who accepted to benefit from a complementary thyroid ultrasonography (US) were included and managed according to the French endocrine society consensus. Prevalence of fTI in our population and malignancy rate was assessed. Results During the inclusion period, 10,171 patients were referred for a FDG PET–CT in our center. Fifty-three patients presenting a known thyroid disease were excluded. Among the remaining 10,118 patients, 127 (1.3%) with 131 fTI were individualized. US could not be performed in 37 patients. The remaining 90 patients (92 fTI) were explored by US ± fine-needle aspiration biopsy (FNAB). US results demonstrated a nodule aspect in 80 cases of which 60 benefited from FNAB. Nineteen of 92 fTI underwent surgery with 10 malignant lesions among the 60 patients performing both US and FNAB. Conclusion The prevalence of fTI discovered on FDG PET–CT in our population was 1.3% with 10 malignant lesions among the 60 patients performing both US and FNAB.

scholarly journals The impact of particulate electron paramagnetic resonance oxygen sensors on fluorodeoxyglucose imaging characteristics detected via positron emission tomography

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Philip E. Schaner ◽  
Ly-Binh-An Tran ◽  
Bassem I. Zaki ◽  
Harold M. Swartz ◽  
Eugene Demidenko ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Oxygen Sensor ◽  
Oxygen Sensors ◽  
Paramagnetic Resonance ◽  
Imaging Characteristics ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
The Impact ◽  
Electron Paramagnetic

AbstractDuring a first-in-humans clinical trial investigating electron paramagnetic resonance tumor oximetry, a patient injected with the particulate oxygen sensor Printex ink was found to have unexpected fluorodeoxyglucose (FDG) uptake in a dermal nodule via positron emission tomography (PET). This nodule co-localized with the Printex ink injection; biopsy of the area, due to concern for malignancy, revealed findings consistent with ink and an associated inflammatory reaction. Investigations were subsequently performed to assess the impact of oxygen sensors on FDG-PET/CT imaging. A retrospective analysis of three clinical tumor oximetry trials involving two oxygen sensors (charcoal particulates and LiNc-BuO microcrystals) in 22 patients was performed to evaluate FDG imaging characteristics. The impact of clinically used oxygen sensors (carbon black, charcoal particulates, LiNc-BuO microcrystals) on FDG-PET/CT imaging after implantation in rat muscle (n = 12) was investigated. The retrospective review revealed no other patients with FDG avidity associated with particulate sensors. The preclinical investigation found no injected oxygen sensor whose mean standard uptake values differed significantly from sham injections. The risk of a false-positive FDG-PET/CT scan due to oxygen sensors appears low. However, in the right clinical context the potential exists that an associated inflammatory reaction may confound interpretation.

scholarly journals Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST

2021 ◽  
Author(s):  
Kazuhiro Kitajima ◽  
Tadashi Watabe ◽  
Masatoyo Nakajo ◽  
Mana Ishibashi ◽  
Hiromitsu Daisaki ◽  
...  
Keyword(s):  
Metabolic Disease ◽  
Malignant Melanoma ◽  
Fdg Pet ◽  
Immune Checkpoint Inhibitor ◽  
Metabolic Response ◽  
Checkpoint Inhibitor ◽  
Response Evaluation ◽  
Pet Ct ◽  
Melanoma Patients ◽  
Fdg Pet Ct

Abstract Objective In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response evaluation and prognosis prediction using standardized uptake value (SUV) harmonization of results obtained with various PET/CT scanners installed at different centers. Materials and methods Malignant melanoma patients (n = 27) underwent FDG-PET/CT examinations before and again 3 to 9 months after therapy initiation (nivolumab, n = 21; pembrolizumab, n = 6) with different PET scanners at five hospitals. EORTC, PERCIST, and imPERCIST criteria were used to evaluate therapeutic response, then concordance of the results was assessed using Cohen’s κ coefficient. Log-rank and Cox methods were employed to determine progression-free (PFS) and overall (OS) survival. Results Complete metabolic response (CMR)/partial metabolic response (PMR)/stable metabolic disease (SMD)/progressive metabolic disease (PMD) with harmonized EORTC, PERCIST, and imPERCIST was seen in 3/5/4/15, 4/5/3/15, and 4/5/5/13 patients, respectively. Nearly perfect concordance between each pair of criteria was noted (κ = 0.939–0.972). Twenty patients showed progression and 14 died from malignant melanoma after a median 19.2 months. Responders (CMR/PMR) showed significantly longer PFS and OS than non-responders (SMD/PMD) (harmonized EORTC: p < 0.0001 and p = 0.011; harmonized PERCIST: p < 0.0001 and p = 0.0012; harmonized imPERCIST: p < 0.0001 and p = 0.0012, respectively). Conclusions All harmonized FDG-PET criteria (EORTC, PERCIST, imPERCIST) showed accuracy for response evaluation of ICI therapy and prediction of malignant melanoma patient prognosis. Additional studies to determine their value in larger study populations will be necessary.

scholarly journals Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review

2020 ◽  
Vol 153 ◽  
pp. 103044 ◽  
Author(s):  
C. Bisschop ◽  
E.C. de Heer ◽  
A.H. Brouwers ◽  
G.A.P. Hospers ◽  
M. Jalving
Keyword(s):  
Systematic Review ◽  
Cutaneous Melanoma ◽  
Fdg Pet ◽  
Rational Use ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer

Pancreas ◽  
2013 ◽  
Vol 42 (1) ◽  
pp. 11-19 ◽  
Author(s):  
Akinori Asagi ◽  
Koji Ohta ◽  
Junichirou Nasu ◽  
Minoru Tanada ◽  
Seijin Nadano ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Fdg Pet ◽  
Clinical Management ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document